(VIANEWS) – RenaissanceRe Hold (RNR), BioMarin Pharmaceutical (BMRN), U.S. Physical Therapy (USPH) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. RenaissanceRe Hold (RNR)
49.2% sales growth and 20.84% return on equity
RenaissanceRe Holdings Ltd., together with its subsidiaries, provides reinsurance and insurance products in the United States and internationally. The company operates through Property, and Casualty and Specialty segments. The Property segment writes property catastrophe excess of loss reinsurance and excess of loss reinsurance to insure insurance and reinsurance companies against natural and man-made catastrophes, including hurricanes, earthquakes, typhoons, and tsunamis, as well as winter storms, freezes, floods, fires, windstorms, tornadoes, explosions, and acts of terrorism; and other property class of products, such as proportional reinsurance, property per risk, property reinsurance, binding facilities, and regional U.S. multi-line reinsurance. The Casualty and Specialty segment writes various classes of products, such as directors and officers, medical malpractice, and professional indemnity; automobile and employer's liability, casualty clash, umbrella or excess casualty, workers' compensation, and general liability; financial and mortgage guaranty, political risk, surety, and trade credit; and accident and health, agriculture, aviation, cyber, energy, marine, satellite, and terrorism. The company distributes its products and services primarily through intermediaries. It also invests in and manages funds. RenaissanceRe Holdings Ltd. was founded in 1993 and is headquartered in Pembroke, Bermuda.
Earnings Per Share
As for profitability, RenaissanceRe Hold has a trailing twelve months EPS of $52.28.
PE Ratio
RenaissanceRe Hold has a trailing twelve months price to earnings ratio of 4.33. Meaning, the purchaser of the share is investing $4.33 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 20.84%.
2. BioMarin Pharmaceutical (BMRN)
9.9% sales growth and 3.11% return on equity
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.
Earnings Per Share
As for profitability, BioMarin Pharmaceutical has a trailing twelve months EPS of $0.77.
PE Ratio
BioMarin Pharmaceutical has a trailing twelve months price to earnings ratio of 118.01. Meaning, the purchaser of the share is investing $118.01 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.11%.
3. U.S. Physical Therapy (USPH)
9.3% sales growth and 7.38% return on equity
U.S. Physical Therapy, Inc., through its subsidiaries, operates outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries. The company operates through two segments, Physical Therapy Operations and Industrial Injury Prevention Services. It offers industrial injury prevention services, including onsite injury prevention and rehabilitation, performance optimization, post-offer employment testing, functional capacity evaluations, and ergonomic assessments through physical therapists and specialized certified athletic trainers for Fortune 500 companies, and other clients comprising insurers and their contractors. The company was founded in 1990 and is based in Houston, Texas.
Earnings Per Share
As for profitability, U.S. Physical Therapy has a trailing twelve months EPS of $1.7.
PE Ratio
U.S. Physical Therapy has a trailing twelve months price to earnings ratio of 55.38. Meaning, the purchaser of the share is investing $55.38 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.38%.
Moving Average
U.S. Physical Therapy’s value is above its 50-day moving average of $91.09 and under its 200-day moving average of $100.46.
4. Grand Canyon Education (LOPE)
6.9% sales growth and 31.45% return on equity
Grand Canyon Education, Inc. provides education services to colleges and universities in the United States. The company's technology services include learning management system, internal administration, infrastructure, and support services; academic services comprises program and curriculum, faculty and related training and development, class scheduling, and skills and simulation lab sites; and counseling services and support include admission, financial aid, and field experience and other counseling services. It also offers marketing and communication services, such as lead acquisition, digital communications strategy, brand identity, market research, media planning and strategy, video, and business intelligence and data science; and back-office services comprising finance and accounting, human resources, audit, and procurement services. The company supports healthcare education programs for 27 universities. Grand Canyon Education, Inc. was founded in 1949 and is based in Phoenix, Arizona.
Earnings Per Share
As for profitability, Grand Canyon Education has a trailing twelve months EPS of $6.37.
PE Ratio
Grand Canyon Education has a trailing twelve months price to earnings ratio of 20.53. Meaning, the purchaser of the share is investing $20.53 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 31.45%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 15.3% and 11%, respectively.
Moving Average
Grand Canyon Education’s worth is under its 50-day moving average of $133.58 and way higher than its 200-day moving average of $118.00.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Grand Canyon Education’s EBITDA is 64.59.
Revenue Growth
Year-on-year quarterly revenue growth grew by 6.3%, now sitting on 941.32M for the twelve trailing months.
5. Amphenol Corporation (APH)
6.7% sales growth and 25.07% return on equity
Amphenol Corporation, together with its subsidiaries, primarily designs, manufactures, and markets electrical, electronic, and fiber optic connectors in the United States, China, and internationally. It operates through three segments: Harsh Environment Solutions, Communications Solutions, and Interconnect and Sensor Systems. The company offers connectors and connector systems, including harsh environment data, power, high-speed, fiber optic, and radio frequency interconnect products; busbars and power distribution systems; and other connectors. It also provides value-add products, such as backplane interconnect systems, cable assemblies and harnesses, and cable management products; other products comprising flexible and rigid printed circuit boards, hinges, other mechanical, and production related products. In addition, the company offers consumer device, network infrastructure, and other antennas; coaxial, power, and specialty cables; and sensors and sensor-based products. It sells its products through its sales force, independent representatives, and a network of electronics distributors to original equipment manufacturers, electronic manufacturing services companies, original design manufacturers, and service providers in the automotive, broadband communication, commercial aerospace, industrial, information technology and data communication, military, mobile device, and mobile network markets. Amphenol Corporation was founded in 1932 and is headquartered in Wallingford, Connecticut.
Earnings Per Share
As for profitability, Amphenol Corporation has a trailing twelve months EPS of $3.11.
PE Ratio
Amphenol Corporation has a trailing twelve months price to earnings ratio of 33.8. Meaning, the purchaser of the share is investing $33.8 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 25.07%.
6. BlackRock Capital Investment Corporation (BKCC)
6.2% sales growth and 4.85% return on equity
BlackRock Capital Investment Corporation, formerly known as BlackRock Kelso Capital Corporation, is a Business Development Company specializing in investments in middle market companies. The fund invests in all industries. It prefers to invest between $10 million and $50 million and can invest more or less in companies with EBITDA or operating cash flow between $10 million and $50 million. The fund invests in the form of senior and junior secured, unsecured, and subordinated debt securities and loans including cash flow, asset backed, and junior lien facilities and equity securities. It's equity investments can be structured in the form of warrants, preferred stock, common equity co-investments, and direct investments in common stock. The fund's debt investments are principally structured to provide for current cash interest and to a lesser extent non-cash interest, particularly with subordinated debt investments, through a pay-in-kind (PIK) feature. It can also make non-control investments.
Earnings Per Share
As for profitability, BlackRock Capital Investment Corporation has a trailing twelve months EPS of $0.22.
PE Ratio
BlackRock Capital Investment Corporation has a trailing twelve months price to earnings ratio of 17.82. Meaning, the purchaser of the share is investing $17.82 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.85%.
Sales Growth
BlackRock Capital Investment Corporation’s sales growth is 14.9% for the ongoing quarter and 6.2% for the next.
Revenue Growth
Year-on-year quarterly revenue growth grew by 33.2%, now sitting on 77.51M for the twelve trailing months.
Moving Average
BlackRock Capital Investment Corporation’s value is above its 50-day moving average of $3.86 and way higher than its 200-day moving average of $3.54.
Yearly Top and Bottom Value
BlackRock Capital Investment Corporation’s stock is valued at $3.92 at 00:22 EST, under its 52-week high of $4.03 and way above its 52-week low of $3.03.
7. Kinross Gold (KGC)
5.6% sales growth and 3.93% return on equity
Kinross Gold Corporation, together with its subsidiaries, engages in the acquisition, exploration, and development of gold properties principally in the United States, Brazil, Chile, Canada, and Mauritania. It is also involved in the extraction and processing of gold-containing ores; reclamation of gold mining properties; and production and sale of silver. Kinross Gold Corporation was founded in 1993 and is headquartered in Toronto, Canada.
Earnings Per Share
As for profitability, Kinross Gold has a trailing twelve months EPS of $0.19.
PE Ratio
Kinross Gold has a trailing twelve months price to earnings ratio of 27.18. Meaning, the purchaser of the share is investing $27.18 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.93%.
Yearly Top and Bottom Value
Kinross Gold’s stock is valued at $5.16 at 00:22 EST, way under its 52-week high of $6.34 and way higher than its 52-week low of $3.40.
Volume
Today’s last reported volume for Kinross Gold is 10654100 which is 15.37% below its average volume of 12589800.
Moving Average
Kinross Gold’s worth is way under its 50-day moving average of $5.77 and under its 200-day moving average of $5.18.
Previous days news about Kinross Gold(KGC)
- According to Zacks on Thursday, 8 February, "We have handpicked a few mining companies, Eldorado Gold Corporation (EGO Quick QuoteEGO – Free Report) , Hudbay Minerals Inc. (HBM Quick QuoteHBM – Free Report) , Agnico Eagle Mines Limited (AEM Quick QuoteAEM – Free Report) and Kinross Gold Corporation (KGC Quick QuoteKGC – Free Report) , which are set to beat earnings estimates this earnings season."
